Institutional members access full text with Ovid®

Share this article on:

Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices

Mosli, Mahmoud H. MD*,†,‡; Feagan, Brian G. MD*,§,‖; Sandborn, William J. MD§,¶; D'Haens, Geert MD, PhD§,**; Behling, Cynthia MD††; Kaplan, Keith MD‡‡; Driman, David K. MD§§; Shackelton, Lisa M. PhD§; Baker, Kenneth A. PhD§; MacDonald, John K. MS*; Vandervoort, Margaret K. MS§; Geboes, Karel MD, PhD‖‖; Levesque, Barrett G. MD§,¶

doi: 10.1097/01.MIB.0000437986.00190.71
Clinical Review Articles

Background: Ulcerative colitis (UC) is an idiopathic inflammatory disorder. Currently, the main goals of treatment are to induce and maintain clinical and/or endoscopic remission. However, evidence indicates that persistent disease activity on colonic biopsies in the setting of clinical or endoscopic remission is an independent predictor of poor outcomes. A number of previous studies have proposed histologic indices for use in specific trials of UC. The aim of this study was to systematically review the existing histological indices for UC and assess their potential use in both patient management and clinical trials.

Methods: We performed a systematic review of histological indices evaluating disease activity in UC. MEDLINE (Ovid), EMBASE (Ovid), PubMed, the Cochrane Library (CENTRAL), and Digestive Diseases Week (DDW) abstracts of randomized and/or controlled trials clinical trials were searched from inception to February 2013 for applicable studies. Data from these studies were reviewed and analyzed.

Results: After systematically applying inclusion criteria, we identified 108 scientific articles including 88 clinical studies and 21 related clinical reviews. Eighteen indices of histological activity in UC were identified and reviewed.

Conclusions: Although multiple histological scoring indices for assessment of UC disease activity currently exist, none of these instruments were developed using a formal validation process and their operating properties remain poorly understood. Future studies are needed to address this deficiency.

Article first published online 9 January 2014

*Department of Medicine, Western University, London, Ontario, Canada;

Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia;

Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada;

§Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, Ontario, Canada;

Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada;

Division of Gastroenterology, University of California San Diego, La Jolla, California;

**Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands;

††Pacific Rim Pathology Medical Corporation, San Diego, California;

‡‡Carolinas Medical Center, Charlotte, North Carolina;

§§Department of Pathology, Western University, London, Ontario, Canada; and

‖‖Department of Pathology, University Hospital of KU Leuven, Leuven, Belgium.

Reprints: Barrett G. Levesque, MD, Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0956 (e-mail: bglevesque@ucsd.edu).

The authors' disclosure statement is available in the Acknowledgments.

Received October 15, 2013

Accepted October 29, 2013

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website